This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (41)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Bacterial Infections  • Infectious Diseases, Other  • Pneumonia  • Alert me on articles by topic

Reba K. Ailani, MD; Gautami Agastya, MD; Rajesh K. Ailani, MD; Beejadi N. Mukunda, MD; Raja Shekar, MD

Arch Intern Med. 1999;159:266-270.

Background  Doxycycline has a high degree of activity against many common respiratory pathogens and has been used in the outpatient management of lower respiratory tract infections, including pneumonia.

Objective  To evaluate the efficacy of intravenous doxycycline as empirical treatment in hospitalized patients with mild to moderately severe community-acquired pneumonia.

Patients and Methods  We conducted a randomized prospective trial to compare the efficacy of intravenous doxycycline with other routinely used antibiotic regimens in 87 patients admitted with the diagnosis of community-acquired pneumonia. Forty-three patients were randomized to receive 100 mg of doxycycline intravenously every 12 hours while 44 patients received other antibiotic(s) (control group). The 2 patient groups were comparable in their clinical and laboratory profiles.

Results  The mean ± SD interval between starting an antibiotic and the clinical response was 2.21 ± 2.61 days in the doxycycline group compared with 3.84 ± 6.39 days in the control group (P = .001). The mean ± SD length of hospitalization was 4.14 ± 3.08 days in the doxycycline group compared with 6.14 ± 6.65 days in the control group (P = .04). The median cost of hospitalization was $5126 in the doxycycline group compared with $6528 in the control group (P = .04). The median cost of antibiotic therapy in the doxycycline-treated patients ($33) was significantly lower than in the control group ($170.90) (P<.001). Doxycycline was as efficacious as the other regimens chosen for the treatment of community-acquired pneumonia.

Conclusion  Doxycycline is an effective and inexpensive therapy for the empirical treatment of hospitalized patients with mild to moderately severe community-acquired pneumonia.

From the Department of Medicine, Meridia Huron Hospital, Cleveland, Ohio.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Empirical Atypical Coverage for Inpatients With Community-Acquired Pneumonia: Systematic Review of Randomized Controlled Trials
Shefet et al.
Arch Intern Med 2005;165:1992-2000.
ABSTRACT | FULL TEXT  

Early Mobilization of Patients Hospitalized With Community-Acquired Pneumonia
Mundy et al.
Chest 2003;124:883-889.
ABSTRACT | FULL TEXT  

Fluoroquinolones for Respiratory Infections : Too Valuable To Overuse
Williams
Chest 2001;120:1771-1775.
FULL TEXT  

BTS Guidelines for the Management of Community Acquired Pneumonia in Adults
Thorax 2001;56:iv1-64.
FULL TEXT  

Guidelines for the Management of Adults with Community-acquired Pneumonia . Diagnosis, Assessment of Severity, Antimicrobial Therapy, and Prevention
Niederman et al.
Am. J. Respir. Crit. Care Med. 2001;163:1730-1754.
FULL TEXT  

Antiviral Agents for Influenza
Johnson and Wenzel
JAMA 2000;283:3069-3070.
FULL TEXT  

The Drug-Resistant Pneumococcus: Clinical Relevance, Therapy, and Prevention
Harwell and Brown
Chest 2000;117:530-541.
ABSTRACT | FULL TEXT  

Treatment for Community Acquired Pneumonia: More Support for Doxycycline
Ditmanson et al.
Arch Intern Med 1999;159:1814-1815.
FULL TEXT